Genewel’s WELPASS Gains Attention in Middle Eastern Medical Device Market

Genewel’s WELPASS, developed by a Korean medical device company, is gaining traction in the Middle Eastern medical device market. Genewel participated in the Arab Health 2025 exhibition in Dubai and held export discussions with 120 companies from 23 countries.

What is WELPASS?

WELPASS is a novel drug delivery kit designed to reduce post-operative pain.

• It combines a local anesthetic and gel.
• The mixture is applied to the surgical site.
• Releases the drug gradually over 72 hours.

Showcasing at Arab Health 2025

During the exhibition, Genewel hosted a showcase with medical professionals who conducted clinical research on WELPASS.

Key Findings from Clinical Research

• The group using WELPASS during thoracoscopic lung surgery required about 8 times less local anesthetic than the control group.
• Pain management was comparable between both groups.
• Additional painkiller use within 48 hours post-surgery was significantly lower in the WELPASS group.

These features drew considerable interest from buyers. Genewel plans to leverage this interest to achieve CE MDR certification for the European market, accelerating its global market entry.

Hyaluronic Acid Filler Introduction

At the exhibition, Genewel also launched a hyaluronic acid filler set to hit global markets in the first half of the year. Highlights of the new filler include:

• Use of Genewel’s biomaterial technology.
• Excellent viscoelasticity and uniform particle structure.
• Easy to inject and offers safety and longevity.

CEO’s Vision for Expansion

Han Sang-Deok, CEO of Genewel, reported increased booth traffic at Arab Health compared to the previous year, with a 20% rise in visitors showing interest in their products. Genewel aims to:

• Expand its product lineup.
• Obtain more global certifications.
• Expand into e-commerce platforms.
• Transition into a global company.

Summary

Genewel’s efforts at Arab Health 2025 showcased cutting-edge medical technology. WELPASS is set to transform post-operative pain management with its unique features and the potential for broad international adoption. Genewel continues to push product development and certification, charting a path toward its goal of becoming a recognized global player in the medical device sector.

Table of Contents:

1. Introduction
   • Overview of Genewel and its market presence in the Middle East
   • Introduction to WELPASS and its significance in pain management
2. What is WELPASS?
   • Description of the drug delivery kit and its components
   • Mechanism of action: gradual release of local anesthetic over 72 hours
3. Showcasing at Arab Health 2025
   • Highlights of Genewel’s participation in the exhibition
   • Interactions with medical professionals conducting clinical research on WELPASS
4. Key Findings from Clinical Research
   • Comparative analysis between WELPASS group and control group during thoracoscopic lung surgery
   • Results on local anesthetic usage and additional painkiller requirements
   • Implications for pain management effectiveness
5. Plans for Global Market Entry
   • Strategy for obtaining CE MDR certification for WELPASS
   • Insights on leveraging positive interest from buyers for international adoption
6. Hyaluronic Acid Filler Introduction
   • Overview of the new hyaluronic acid filler launched at Arab Health
   • Highlight features: biomaterial technology, viscoelasticity, and user friendliness
7. CEO’s Vision for Expansion
   • Statements from Han Sang-Deok on increased booth traffic and growing interest
   • Goals for expanding product lineup, obtaining global certifications, and venturing into e-commerce
8. Summary
   • Recap of Genewel’s innovative offerings and strategic aspirations
   • Outlook on WELPASS’s potential impact on post-operative pain management and global reach